Cargando…

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations

INTRODUCTION: When darunavir (DRV) 800 mg is boosted with 150 mg cobicistat (DRV (cobi)), DRV trough concentration (C(trough)) is about 30% lower as compared to 100 mg ritonavir (DRV (rtv)). DRV (cobi) shows similar virological efficacy as DRV (rtv) when combined with two nucleos(t)ide analogue reve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutierrez‐Valencia, Alicia, Trujillo‐Rodriguez, Maria, Fernandez‐Magdaleno, Tamara, Espinosa, Nuria, Viciana, Pompeyo, López‐Cortés, Luis F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808101/ https://www.ncbi.nlm.nih.gov/pubmed/29430854 http://dx.doi.org/10.1002/jia2.25072

Ejemplares similares

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
por: BenMarzouk-Hidalgo, Omar J., et al.
Publicado: (2015)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients
por: López-Ruz, Miguel A., et al.
Publicado: (2018)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Data on the stability of darunavir/cobicistat suspension after tablet manipulation
por: Zanon, D., et al.
Publicado: (2020)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2022)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
por: Di Castelnuovo, Augusto, et al.
Publicado: (2021)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
por: Gisslén, Magnus, et al.
Publicado: (2012)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
por: Mandelbrot, Laurent, et al.
Publicado: (2023)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Ceftriaxone/cobicistat/darunavir/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy
por: Colbers, Angela, et al.
Publicado: (2015)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
por: Suárez-García, Inés, et al.
Publicado: (2020)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
por: Squillace, Nicola, et al.
Publicado: (2018)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients
por: Lopez-Ruz, Miguel A., et al.
Publicado: (2016)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2012)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
por: Kim, Eun Jin, et al.
Publicado: (2020)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
por: Zorrilla, CD, et al.
Publicado: (2014)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rbpqohnfgumaj2mbokjnv114vt